Lupin has entered into a strategic joint venture agreement with
Toyama based Japanese pharmaceuticals company, Yoshindo Inc. (Yoshindo)
to create a new entity, YL Biologics (YLB). YLB will be jointly managed
by both partners and will be responsible for conducting clinical
development of certain Biosimilars including regulatory filings and
obtaining marketing authorizations in Japan.For more information ✆ - 0731-6642300 or Visit https://www.epicresearch.co/
No comments:
Post a Comment